Trial Profile
Phase I trial of ALN-HTT, an RNAi drug-device combination product, for the treatment of Huntington's disease.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 02 Mar 2012
Price :
$35
*
At a glance
- Drugs ALN HTT (Primary)
- Indications Huntington's disease
- Focus Pharmacodynamics; Therapeutic Use
- 02 Mar 2012 New trial record